Trade with Eva: Analytics in action >>

Wednesday, March 13, 2019

-=Lexicon Pharma (LXRX) reported earnings on Wed 13 March 19 (b/o)



Lexicon Pharma beats by $0.12, beats on revs
  • Reports Q4 (Dec) loss of $0.16 per share, $0.12 better than the S&P Capital IQ Consensus of ($0.28); revenues fell 49.7% year/year to $17.1 mln vs the $13.33 mln S&P Capital IQ Consensus.
  • Anticipated Upcoming Milestones
    • Q1 2019 -- Manuscript publications for XERMELO in carcinoid syndrome diarrhea
    • Q1 2019 -- Initiation of a Phase 1b study for LX9211
    • March 22, 2019 -- PDUFA date for sotagliflozin in type 1 diabetes in the U.S.
    • Q2 2019 -- European Commission decision on marketing application for sotagliflozin in type 1 diabetes in the EU

No comments:

Post a Comment